# Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors

> **NCT00364143** · PHASE1 · COMPLETED · sponsor: **Yakult Honsha Co., LTD** · enrollment: 40 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** IHL-305 (irinotecan liposome injection)

## Key facts

- **NCT ID:** NCT00364143
- **Lead sponsor:** Yakult Honsha Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2011-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00364143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00364143, "Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00364143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*